-

Global Coronavirus Disease 2019 (COVID-19) Clinical Trials Research Report 2021 - Overview, Landscape, Trial using Vaccines vs. Therapeutics, and Trials Impacted by COVID-19 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Coronavirus Disease 2019 (COVID-19) Clinical Trials - Overview, Landscape, Trial using Vaccines vs. Therapeutics, and Trials Impacted by COVID-19" report has been added to ResearchAndMarkets.com's offering.

The purpose of this report is to provide insight into the overall clinical trial landscape for COVID-19 clinical trials, trials using vaccines vs. therapeutics, and trials impacted by COVID-19.

Scope

  • The clinical trials data used for these analyses were extracted from the publisher's Clinical Trials Database.
  • The data included clinical trials that were captured in the database as of April 22, 2021.
  • The trials were analyzed and segmented by all COVID-19 trials, trials using vaccines, trials using therapeutics, and non-COVID-19 trials impacted due to the pandemic. Further analysis was conducted based on multinational vs. single country, clinical trial sites, status, primary endpoint status, terminated trials, phase, sponsor type, and upcoming milestone events.

Reasons to Buy

  • Understand the global COVID-19 landscape
  • The trends of vaccine COVID-19 clinical trials
  • The trends of therapeutic COVID-19 clinical trials
  • A closer look at the impact of the pandemic on non-COVID-19 trials

Key Topics Covered:

Executive Summary

  • Introduction
  • Analysis of COVID-19 Clinical Trials
  • COVID-19 Clinical Trials for Vaccines
  • COVID-19 Clinical Trials for Therapeutics
  • Impact of COVID-19 on Clinical Trials
  • Key Findings
  • Appendix

Key Tables

  • Top Countries with COVID-19 Key Stats

Key Figures

  • Impact of COVID-19
  • Top Countries in COVID-19 Key Stats
  • Landscape of Pipeline Candidates for COVID-19, by Phase
  • Landscape of Vaccines Candidates for COVID-19, by Phase
  • Number of COVID-19 Clinical Trials by Start Date, by Month
  • Number of COVID-19 Clinical Trials, by Multinational vs. Single Country
  • Single Country COVID-19 Clinical Trials, By Region & Phase
  • Multinational Country COVID-19 Clinical Trials, By Region & Phase
  • COVID-19 Clinical Trial Sites, by Region
  • COVID-19 Clinical Trial Sites, by Country & State
  • Number of COVID-19 Clinical Trials, by Phase & Status
  • Endpoint Status for Completed COVID-19 Clinical Trials
  • Top Reasons for Terminated Trials, by Phase
  • Top Reason for Terminated Trials, by Sponsor Type
  • COVID-19 Clinical Trials by Vaccine, by Month
  • Vaccine COVID-19 Clinical Trials, by Phase & Status
  • Vaccine COVID-19 Clinical Trials, by Sponsor Type
  • Top Industry Sponsors for COVID-19 Vaccine Clinical Trials
  • Top Non-Industry Sponsors for COVID-19 Vaccine Clinical Trials
  • Pfizer/BioNTech's Tozinameran (Comirnaty), by Status & Phase
  • Moderna's mRNA-1273, by Status & Phase
  • Johnson & Johnson's JNJ-78436735, by Status & Phase
  • AstraZeneca's Covishield (Vaxzevria), by Status & Phase
  • Bharat Biotech's Covaxin, by Status & Phase
  • CanSino Biologics' Convidecia, by Status & Phase
  • SinoVac Biotech's CoronaVac, by Status & Phase
  • Upcoming Filings and Regulatory Approvals for COVID-19 Vaccines
  • Clinical Trial Start Date to First Approval for Vaccines
  • COVID-19 Therapeutic Clinical Trials, by Month
  • Therapeutic COVID-19 Clinical Trials, by Phase & Status
  • Therapeutic COVID-19 Clinical Trials, by Sponsor Type
  • Top Industry Sponsors for COVID-19 Therapeutic Clinical Trials
  • Top Non-Industry Sponsors for COVID-19 Therapeutic Clinical Trials
  • Gilead Sciences' Remdesivir (Veklury), by Status & Phase
  • Fujifim Toyama Chemical's Favipiravir, by Status & Phase
  • Eli Lilly's Bamlanivimab, by Status & Phase
  • Regeneron's Casirivimab + Imdevimab, by Status & Phase
  • Eli Lilly's Baricitinib, by Status & Phase
  • CytoDyn's Leronlimab, by Status & Phase
  • Upcoming Filings and Regulatory Approvals for Therapeutic COVID-19 Drugs
  • Clinical Trials Disrupted Due to COVID-19
  • Disrupted Clinical Trials, by Reason
  • Disrupted Clinical Trials, by Therapy Area
  • Disrupted Clinical Trials Activities
  • Disrupted Clinical Trials, by Top Sponsors
  • Resumed Clinical Trials, by Top Five Therapy Areas

For more information about this report visit https://www.researchandmarkets.com/r/f32tlb

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Poland Investment Funds and Asset Management Market Report 2026, Profiles of TFI, Pekao, Santander, PKO, Allianz, Goldman Sachs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Investment Funds and Asset Management Market in Poland, 2024-2026" report has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive overview of the investment funds and asset management sector in Poland. Analysis covers the main pillars of the market, including: mutual funds, insurance, and pension assets. The report also mid-term forecast of key volumes for the period 2025-2027. The data has been presented in a form of horizontal pr...

Europe Data Center Colocation Market Outlook & Forecast Report 2025-2030 Featuring Major Players - Digital Realty, Equinix, NTT DATA, Global Switch, CyrusOne, Ark Data Centres - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Europe Data Center Colocation Market - Industry Outlook & Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. The Europe Data Center Colocation Market was valued at USD 9.45 Billion in 2024, and is projected to reach USD 35.73 Billion by 2030, rising at a CAGR of 24.82%. The Europe data center colocation market is expected to witness cumulative investments of approximately $144.03 billion, of which, the Western Europe is slated to ac...

GCC Construction Equipment Market Research Report 2025-2030 Featuring Key Vendors - Caterpillar, Komatsu, Volvo, Hitachi, SANY, XCMG, JCB, Liebherr, Kobelco, and Zoomlion - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "GCC Construction Equipment Market Research Report 2025-2030" report has been added to ResearchAndMarkets.com's offering. The GCC Construction Equipment Market was sized at 68,499 Units in 2024, and is projected to reach 94,499 Units by 2030, rising at a CAGR of 5.51%. Governments in the UAE and Saudi Arabia continue to prioritize urban growth and diversification, with Dubai's long-term 2040 Urban Master Plan and the Saudi Vision 2030-linked mega-projects fuelling o...
Back to Newsroom